FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
- 1 January 2005
- journal article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 25 (1), 191-207
- https://doi.org/10.1148/rg.251045045
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantationBlood, 2003
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003
- Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantationLeukemia, 2002
- Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin diseaseBlood, 2001
- Benign causes of 18-FDG uptake on whole body imagingSeminars in Nuclear Medicine, 1998
- Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumorsCancer, 1998
- Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Diffusely Increased Colonic F-18 FDG Uptake in Acute EnterocolitisClinical Nuclear Medicine, 1995
- Increased F-18 FDG Accumulation in an Acute FractureClinical Nuclear Medicine, 1994
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993